Is atomoxetine (Strattera) used off‑label for depression or anxiety?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Is Strattera (Atomoxetine) Used Off-Label for Depression or Anxiety?

Strattera is NOT FDA-approved for depression or anxiety—it is approved exclusively for ADHD treatment in children, adolescents, and adults 1, 2. However, off-label use has been explored in research settings with mixed results, and clinicians should understand both the regulatory status and the emerging evidence.

FDA-Approved Indication

Atomoxetine is approved only for ADHD treatment across all age groups 1. The FDA label contains no indication for primary depression or anxiety disorders 2. This is the regulatory reality that frames all clinical decision-making.

Off-Label Use: What the Evidence Shows

For Depression

Limited research suggests atomoxetine may have antidepressant augmentation potential, but this is not standard practice:

  • Augmentation strategy: One small open-label study (N=15) showed 60% response when atomoxetine was added to existing antidepressants in partial responders 3. However, this was uncontrolled and involved patients already on antidepressants—not monotherapy for depression.

  • ADHD with comorbid mood symptoms: Atomoxetine improved depressive symptoms in children with ADHD and comorbid mood disorders, though improvement was slower than in ADHD-only patients 4. This suggests benefit for depressive symptoms in the context of ADHD, not primary depression.

Critical caveat: The FDA label warns about increased suicidal ideation risk in children and adolescents taking atomoxetine 1, 2. This black-box warning makes off-label use for depression particularly problematic, especially in younger patients.

For Anxiety

The evidence is more nuanced but still does not support primary anxiety treatment:

  • Does not worsen anxiety in ADHD patients: Two well-designed trials demonstrated atomoxetine does not exacerbate anxiety in ADHD patients with comorbid anxiety disorders 2. A pediatric trial (N=176) and an adult trial (N=442) both showed no worsening on anxiety rating scales.

  • May reduce anxiety symptoms in ADHD: Multiple studies show anxiety symptom reduction when treating ADHD patients with comorbid anxiety 5, 6, 7, 8. One study found atomoxetine as adjunctive treatment reduced anxiety in adults with ADHD and partially responsive generalized anxiety on SSRIs/SNRIs 6.

  • Mechanism: As a norepinephrine reuptake inhibitor, atomoxetine's anxiolytic effects likely occur through improved prefrontal cortex regulation in ADHD patients, not through direct anxiolytic action 1.

Clinical Algorithm for Decision-Making

Use atomoxetine ONLY when:

  1. Primary diagnosis is ADHD (confirmed by DSM criteria)
  2. Depression or anxiety is comorbid, not the primary disorder
  3. You need to avoid stimulants (cardiovascular concerns, substance abuse history, patient preference)
  4. You are monitoring closely for suicidal ideation (especially in youth) 1

Do NOT use atomoxetine when:

  1. Depression or anxiety is the primary diagnosis without ADHD
  2. Patient has cardiovascular disease, narrow-angle glaucoma, or urinary retention 9
  3. Patient is on CYP2D6 inhibitors (SSRIs can elevate atomoxetine levels significantly) 1
  4. You need rapid symptom control (atomoxetine takes 4-6 weeks for full effect)

Safety Monitoring Requirements

If using atomoxetine in ADHD patients with comorbid mood/anxiety symptoms:

  • Blood pressure and heart rate: Monitor at every visit, as 5-10% of adults experience clinically significant increases 2, 9
  • Suicidal ideation: Close monitoring required, especially first few months and during dose changes 1, 2
  • Hepatic function: Dose adjustment needed in moderate-to-severe hepatic impairment 2
  • Drug interactions: Particularly with CYP2D6 inhibitors (fluoxetine, paroxetine) 1

Bottom Line

Atomoxetine should not be prescribed as primary treatment for depression or anxiety disorders. Its role is limited to ADHD treatment, where it may provide the secondary benefit of not worsening—and possibly improving—comorbid anxiety or depressive symptoms 5, 6, 8, 4. The one exception where off-label use has preliminary support is as augmentation to antidepressants in treatment-resistant depression 3, but this remains investigational and should only be attempted by specialists comfortable managing the cardiovascular and suicidality risks.

For primary depression or anxiety without ADHD, use FDA-approved treatments (SSRIs, SNRIs, CBT) rather than atomoxetine.

References

5
Research

Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms.

Journal of the American Academy of Child and Adolescent Psychiatry, 2005

Related Questions

I have major depressive disorder, generalized anxiety disorder, and attention‑deficit/hyperactivity disorder, and I am taking citalopram 40 mg daily and atomoxetine (Strattera) 80 mg daily, but I continue to experience low mood and depressive symptoms. What treatment options should I consider?
What is the appropriate dosing and monitoring strategy for Strattera (atomoxetine) in an adult with ADHD when combined with Prozac (fluoxetine) for anxiety?
For a patient who meets criteria for generalized anxiety disorder and ADHD and is about to start atomoxetine (Strattera), would she benefit from adding an SSRI?
Is Strattera (atomoxetine) a good first-line treatment for a patient with Attention Deficit Hyperactivity Disorder (ADHD), Post-Traumatic Stress Disorder (PTSD), Major Depressive Disorder (MDD), and anxiety?
What is the recommended treatment plan for a client on atomoxetine for ADHD who continues to experience panic attacks?
What are the most common cysts of the scalp?
What does a PHQ-9 score of 11 indicate and what is the recommended management?
What is an inexpensive prescription treatment for melasma?
What are the top three differential diagnoses for this case?
How should a newborn with hypothermia and bradycardia be evaluated and managed?
Is mirtazapine appropriate for stimulating appetite in a patient with poor appetite?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.